Interactive · Case-Based · CME-Accredited
This comprehensive educational program brings together three accredited learning experiences designed to advance your understanding and management of ulcerative colitis (UC), from foundational mechanisms to real-world treatment strategies and the latest therapeutic innovations.
Led by Dr. Ayal Hirsch (Sheba Medical Center) and Prof. Uri Kopylov (Sheba Medical Center), both internationally recognized experts in inflammatory bowel disease, the program combines evidence-based lectures, interactive case discussions, and focused microlearning sessions. Each component builds toward practical, patient-centered approaches that reflect the evolving UC treatment landscape.
Rating: 5/5
CME/CPD: 3Â Credit
Duration: 3 hours
By completing the full program, learners will be able to:
- Understand UC’s underlying mechanisms and its clinical impact.
- Evaluate and integrate emerging therapies into personalized treatment plans.
- Strengthen patient communication and shared decision-making.
- Apply guideline-based management strategies in complex and special-case scenarios.
This activity is supported by an educational grant from Pfizer.
Course 1
Advancing Care: Breakthroughs in Diagnosing and Treating UC
Gain a deep understanding of UC pathophysiology, patient burden, and cutting-edge therapies, including IL-23 inhibitors, JAK inhibitors, and S1P receptor modulators.
Course 2
Microlearning: Ulcerative Colitis Treatment Innovations
A series of concise, interactive lessons highlighting oral small molecules and special clinical considerations in adolescents and patients with isolated proctitis.
Course 3
Interactive Workshop: Personalized Treatment Plans for UC
Apply knowledge through two real-world patient cases that explore shared decision-making, disease severity, and individualized treatment pathways.
This program is supported by an independent educational grant from Pfizer.
Participants can earn up to 3 CME/CPD credits upon completing all three activities.